Stand Up to Cancer Awards $9.7 Million to Young Researchers

Stand Up to Cancer, an initiative of the Entertainment Industry Foundation, has announced grants totaling nearly $9.7 million to thirteen young scientists to conduct high-risk, high-reward cancer research projects.

Awarded through SU2C's Innovative Research Grants program, which supports the next generation of cancer research leaders, the three-year grants of up to $750,000 will support projects that offer new approaches to some of the most important and challenging problems facing cancer researchers today. Addressing a wide range of cancer types and organ sites, including leukemia, lymphomas, and lung, ovarian, and breast cancers, the projects all have the potential to significantly advance the identification of the complex mechanisms that cause cancers to occur and spread, lead to the development of a new generation of targeted treatments, and improve the methods of diagnosing cancers and monitoring the effects of treatment.

Grant recipients include Fernando D. Camargo, Children's Hospital Boston; Elizabeth R. Lawlor, Children's Hospital Los Angeles; Matthew Levy, Albert Einstein College of Medicine of Yeshiva University; Markus Müschen, Children's Hospital Los Angeles; William Pao, Vanderbilt-Ingram Cancer Center/Vanderbilt University; Charles M. Roberts, Dana-Farber Cancer Institute; Rajat Rohatgi, Stanford University; José M. Silva, Columbia University Medical Center; Kimberly Stegmaier, Dana-Farber Cancer Institute; Muneesh Tewari, Fred Hutchinson Cancer Research Center; Loren D. Walensky, Dana-Farber Cancer Institute; David M. Weinstock, Dana-Farber Cancer Institute; and Hang Yin, University of Colorado at Boulder.

"We asked our best and brightest young researchers to step outside their comfort zones and strive to make big differences with bold initiatives," said Richard D. Kolodner, professor of medicine at the University of California, San Diego, and chairman of the grants review committee. "If these projects come to fruition, some of the ideas could be game-changers in cancer research."